Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
drospirenone + ethinyl estradiol
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Drospirenone + ethinyl estradiol is a combined oral contraceptive (COC) consisting of a synthetic estrogen (ethinyl estradiol) and a fourth-generation progestin (drospirenone). Drospirenone is unique among progestins for its anti-mineralocorticoid and anti-androgenic properties, which can help mitigate estrogen-related water retention and acne. In the context of endometriosis, this combination therapy works by suppressing the hypothalamic-pituitary-ovarian axis, thereby inhibiting ovulation and inducing decidualization and subsequent atrophy of endometrial tissue. This leads to a reduction in the volume of endometriotic lesions and a decrease in the production of inflammatory mediators, effectively managing endometriosis-associated pelvic pain (EAPP) and dysmenorrhea. The drug is being utilized as an active comparator in a Phase 4 clinical trial conducted by the Women's Hospital School of Medicine Zhejiang University to evaluate the efficacy of low-dose aspirin for pain management in endometriosis patients.
- Brand names
- YasminYazOcellaSyedaZarahGianviLorynaNikki
- Other names
- drospirenone/ethinyl estradiolEE/DRSP
02
Targets
MR (Mineralocorticoid receptor)ER (Estrogen receptor)PR (Progesterone receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on drospirenone + ethinyl estradiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on drospirenone + ethinyl estradiol.